Literature DB >> 19934622

Glucose control in the older patient: from intensive, to effective and safe.

Ligia J Dominguez1, Giuseppe Paolisso, Mario Barbagallo.   

Abstract

Older adults represent an extensive proportion of Type 2 diabetic patients. Managing diabetes in this population is challenging, because complex comorbidity and disability often mean that guidelines are not suitable on an individual basis. Recent evidence has raised animated discussion of the possibility that intensive glucose control may cause more harm than benefit, especially in older adults. The benefit of glycemic control on microvascular diabetic complications has been consistently demonstrated, but the evidence of benefit on macrovascular disease is not uniform in all studies. Glycemic control appears to prevent the development of cardiovascular events, but is less helpful in secondary prevention, when cardio- and cerebro-vascular diseases are established. In addition, treating hyperglycemia in critically ill patients (most of them over 60 years old) with a target close to normal glucose values has been shown to increase morbidity and mortality. It is possible that the attempt to reach euglycemia is not the best goal, in either older non-diabetic critically ill patients or older diabetic adults. The risks associated with hypoglycemia, which induces a counter-regulatory response with prolonged QT interval and cardiac arrhythmias in patients with established cardiovascular disease, should be carefully considered. The reported association of hypoglycemia with dementia and falls should also be examined. In the older adult, prudent, personalized therapy, with less rigid targets for patients at higher risk of hypoglycemia, is essential. The use of agents with a good safety profiles and with the least possibility of causing hypoglycemia is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19934622     DOI: 10.1007/BF03337724

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  9 in total

1.  Choice of long-acting insulin therapy for type 2 diabetes: how can treatment for older people be optimized?

Authors:  Andrew J Krentz; Alan J Sinclair
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

2.  Choosing targets for glycaemia, blood pressure and low-density lipoprotein cholesterol in elderly individuals with diabetes mellitus.

Authors:  Susan R Kirsh; David C Aron
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

3.  Preservation of blood glucose homeostasis in slow-senescing somatotrophism-deficient mice subjected to intermittent fasting begun at middle or old age.

Authors:  Oge Arum; Jamal K Saleh; Ravneet K Boparai; John J Kopchick; Romesh K Khardori; Andrzej Bartke
Journal:  Age (Dordr)       Date:  2014-05-01

Review 4.  Type 2 diabetes mellitus and Alzheimer's disease.

Authors:  Mario Barbagallo; Ligia J Dominguez
Journal:  World J Diabetes       Date:  2014-12-15

5.  Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study.

Authors:  Alfred Penfornis; Béatrice Fiquet; Jean Frédéric Blicklé; Sylvie Dejager
Journal:  Diabetes Metab Syndr Obes       Date:  2015-07-03       Impact factor: 3.168

Review 6.  Disease burden evaluation of fall-related events in the elderly due to hypoglycemia and other diabetic complications: a clinical review.

Authors:  Usman H Malabu; Venkat N Vangaveti; Richard Lee Kennedy
Journal:  Clin Epidemiol       Date:  2014-08-14       Impact factor: 4.790

Review 7.  Traumatic injuries in patients with diabetes mellitus.

Authors:  Ayman El-Menyar; Ahammed Mekkodathil; Hassan Al-Thani
Journal:  J Emerg Trauma Shock       Date:  2016 Apr-Jun

8.  Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.

Authors:  M A Boustani; I Pittman; M Yu; V T Thieu; O J Varnado; R Juneja
Journal:  Diabetes Obes Metab       Date:  2016-06-07       Impact factor: 6.577

9.  Specific suppression of insulin sensitivity in growth hormone receptor gene-disrupted (GHR-KO) mice attenuates phenotypic features of slow aging.

Authors:  Oge Arum; Ravneet K Boparai; Jamal K Saleh; Feiya Wang; Angela L Dirks; Jeremy G Turner; John J Kopchick; Jun-Li Liu; Romesh K Khardori; Andrzej Bartke
Journal:  Aging Cell       Date:  2014-09-20       Impact factor: 9.304

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.